UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 216

Sortiert nach

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

Cancer treatment reviews, 2020-06, Vol.86, p.102017-102017, Article 102017

2020

Volltextzugriff (PDF)

The Role of MET Receptor Tyrosine Kinase in Non‐Small Cell Lung Cancer and Clinical Development of Targeted Anti‐MET Agents

The oncologist (Dayton, Ohio), 2013-02, Vol.18 (2), p.115-122

2013

Volltextzugriff (PDF)

Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study

Clinical cancer research, 2008-03, Vol.14 (5), p.1407-1412

2008

Volltextzugriff (PDF)

Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599

Journal of clinical oncology, 2010-02, Vol.28 (6), p.949-954

2010

Volltextzugriff (PDF)

Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599

Journal of clinical oncology, 2008-01, Vol.26 (1), p.60-65

2008

Volltextzugriff (PDF)

Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501

Journal of clinical oncology, 2009-12, Vol.27 (35), p.6006-6011

2009

Volltextzugriff (PDF)

Invisible Barriers to Clinical Trials: The Impact of Structural, Infrastructural, and Procedural Barriers to Opening Oncology Clinical Trials

Journal of clinical oncology, 2006-10, Vol.24 (28), p.4545-4552

2006

Volltextzugriff (PDF)

Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non–Small-Cell Lung Cancer Treated With Carboplatin and Paclitaxel Plus Bevacizumab

Journal of clinical oncology, 2009-03, Vol.27 (9), p.1405-1412

2009

Volltextzugriff (PDF)

Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib

Journal of clinical oncology, 2008-03, Vol.26 (9), p.1472-1478

2008

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

Clinical cancer research, 2008-07, Vol.14 (14), p.4517-4525

2008

Volltextzugriff (PDF)

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5407-5415

2008

Volltextzugriff (PDF)

Inhibition of angiogenesis in the treatment of non‐small cell lung cancer

Cancer science, 2007-12, Vol.98 (12), p.1825-1830

2007

Volltextzugriff (PDF)

Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732

Journal of clinical oncology, 2005-06, Vol.23 (16), p.3752-3759

2005

Volltextzugriff (PDF)

Phase II Clinical Trial of the Epothilone B Analog, Ixabepilone, in Patients With Non–Small-Cell Lung Cancer Whose Tumors Have Failed First-Line Platinum-Based Chemotherapy

Journal of clinical oncology, 2007-08, Vol.25 (23), p.3448-3455

2007

Volltextzugriff (PDF)

A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non–Small Cell Lung Cancer

Clinical cancer research, 2009-03, Vol.15 (6), p.2158-2165

2009

Volltextzugriff (PDF)

Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer

Clinical cancer research, 2004-06, Vol.10 (12), p.4258s-4262s

2004

Volltextzugriff (PDF)

Steps and Time to Process Clinical Trials at the Cancer Therapy Evaluation Program

Journal of clinical oncology, 2009-04, Vol.27 (11), p.1761-1766

2009

Volltextzugriff (PDF)

Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of Cancer and Leukemia Group B

Journal of clinical oncology, 2006-10, Vol.24 (28), p.4553-4557

2006

Volltextzugriff (PDF)

Body Mass Index and Its Association with Clinical Outcomes for Advanced Non–Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials

Journal of thoracic oncology, 2013-09, Vol.8 (9), p.1121-1127

2013

Volltextzugriff (PDF)

Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition)

Chest, 2007-09, Vol.132 (3 Suppl), p.277S

2007

Volltextzugriff (PDF)

Epidermal growth factor receptor: a promising target in solid tumours

Cancer treatment reviews, 2004-02, Vol.30 (1), p.1-17

2004

Volltextzugriff (PDF)

Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer

Clinical lung cancer, 2012-09, Vol.13 (5), p.391-395

2012

Volltextzugriff (PDF)

Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents

Clinical cancer research, 2006-07, Vol.12 (14 Pt 2), p.4365s-4371s

2006

Volltextzugriff (PDF)

Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab

Journal of thoracic oncology, 2012-09, Vol.7 (9), p.1361-1368

2012

Volltextzugriff (PDF)

Chemotherapy for small cell lung cancer

Seminars in oncology, 2003-02, Vol.30 (1), p.9-25

Sandler, Alan B.

2003

Volltextzugriff (PDF)

1 – 25 von 216

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(206)
Mit Volltextzugriff
(197)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(144)
Science & Technology
(137)
Life Sciences & Biomedicine
(136)
Female
(90)
Oncology
(83)
Biological And Medical Sciences
(74)
Medical Sciences
(74)
Male
(72)
Middle Aged
(63)
Lung Neoplasms - Drug Therapy
(57)
Adult
(56)
Aged
(50)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(44)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(35)
Pharmacology. Drug Treatments
(32)
Lung Neoplasms - Pathology
(29)
Tumors
(29)
Treatment Outcome
(27)
Antineoplastic Agents
(25)
Chemotherapy
(25)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

The Role of MET Receptor Tyrosine Kinase in Non‐Small Cell Lung Cancer and Clinical Development of Targeted Anti‐MET Agents

Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study

Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599

Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599

Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501

Invisible Barriers to Clinical Trials: The Impact of Structural, Infrastructural, and Procedural Barriers to Opening Oncology Clinical Trials

Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non–Small-Cell Lung Cancer Treated With Carboplatin and Paclitaxel Plus Bevacizumab

Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Inhibition of angiogenesis in the treatment of non‐small cell lung cancer

Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732

Phase II Clinical Trial of the Epothilone B Analog, Ixabepilone, in Patients With Non–Small-Cell Lung Cancer Whose Tumors Have Failed First-Line Platinum-Based Chemotherapy

A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non–Small Cell Lung Cancer

Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer

Steps and Time to Process Clinical Trials at the Cancer Therapy Evaluation Program

Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of Cancer and Leukemia Group B

Body Mass Index and Its Association with Clinical Outcomes for Advanced Non–Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials

Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition)

Epidermal growth factor receptor: a promising target in solid tumours

Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer

Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents

Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab

Chemotherapy for small cell lung cancer

Suchergebnisse filtern